Investigating how T cells affect muscle disease in inclusion body myositis
High-dimensional mass imaging of muscle for the mechanistic study of T cells in inclusion body myositis
This study is looking at how certain immune cells called T cells might affect muscle loss in people with sporadic inclusion body myositis (IBM), and it hopes to find new ways to help manage the disease by understanding these cells better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10797018 on NIH RePORTER |
What this research studies
This research focuses on sporadic inclusion body myositis (IBM), a rare muscle disease, by examining the role of T cells in its progression. The study aims to understand how T cells, which can become senescent and lose their ability to proliferate, contribute to muscle cell death in IBM. Researchers will analyze the molecular characteristics of these T cells and their correlation with clinical measures of the disease. Additionally, they will explore pharmacological approaches to regulate T cell senescence, potentially leading to new treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sporadic inclusion body myositis.
Not a fit: Patients with other forms of muscle diseases or those without a diagnosis of inclusion body myositis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with inclusion body myositis.
How similar studies have performed: While the specific approach of this research is novel, previous studies have shown that understanding T cell behavior can lead to advancements in treating autoimmune diseases.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Villalta, Sergio Armando — University of California-Irvine
- Study coordinator: Villalta, Sergio Armando
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.